E3200: efficacy of Avastin^© plus FOLFOX4 in second-line mCRC

E3200: trial design⁹

• E3200 was a phase III trial of Avastin^© in combination with FOLFOX4 in previously treated (irinotecan-based regimen) patients with mCRC.⁹
• Patients were randomised to one of three treatment arms until PD
  • Avastin^© 10mg/kg alone every 2 weeks
  • FOLFOX4
  • FOLFOX4 plus Avastin^© 10mg/kg every 2 weeks.

• The Avastin^© -alone arm was closed to further enrolment based on a review of early results by the ECOG data monitoring committee. Randomisation to the remaining two treatment arms continued.
• The addition of Avastin^© to FOLFOX4 resulted in a statistically significant increase in OS and in PFS.

• Primary endpoint
  • OS.

• Secondary endpoint
  • PFS
  • response rate
  • safety.

E3200: effect of second-line Avastin^© in combination with FOLFOX4 on OS

• Median OS was significantly increased in the Avastin^© plus FOLFOX4 combination therapy arm compared with FOLFOX4 alone (12.9 vs 10.8 months; HR=0.75; p=0.0011).⁹